Comparing the Relative and Absolute Effect of Erenumab: is a 50% Response Enough? Results from the ESTEEMen Study
Ornello Raffaele,Baraldi Carlo,Guerzoni Simona,Lambru Giorgio,Andreou Anna P.,Raffaelli Bianca,Gendolla Astrid,Barbanti Piero,Aurilia Cinzia,Egeo Gabriella,Cevoli Sabina,Favoni Valentina,Vernieri Fabrizio,Altamura Claudia,Russo Antonio,Silvestro Marcello,Valle Elisabetta Dalla,Mancioli Andrea,Ranieri Angelo,Alfieri Gennaro,Latysheva Nina,Filatova Elena,Talbot Jamie,Cheng Shuli,Holle Dagny,Scheffler Armin,Nežádal Tomáš,Čtrnáctá Dana,Šípková Jitka,Matoušová Zuzana,Casalena Alfonsina,Maddestra Maurizio,Viola Stefano,Affaitati Giannapia,Giamberardino Maria Adele,Pistoia Francesca,Reuter Uwe,Sacco Simona The Journal of Headache and Pain（2022）
Key words
Erenumab,Treatment efficacy,Migraine frequency,Real-world
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper